MAP2K7 and neoplasm: Furthermore, the patient’s tumor harbored amplifications of BRAF, EGFR, MET, and CDK6, which provides a rationale for this tumor’s acquired resistance to the triple BRAF/MEK/CDK4&6 inhibitor treatment applied before sequencing [71, 72].